GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (OTCPK:DVHGF) » Definitions » 3-Month Share Buyback Ratio

DVHGF (Devonian Health Group) 3-Month Share Buyback Ratio : 0.00% (As of Jan. 2025 )


View and export this data going back to 2022. Start your Free Trial

What is Devonian Health Group 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Devonian Health Group's current 3-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of Devonian Health Group's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, Devonian Health Group's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Devonian Health Group's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Devonian Health Group's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Devonian Health Group's 3-Month Share Buyback Ratio falls into.


;
;

Devonian Health Group 3-Month Share Buyback Ratio Calculation

Devonian Health Group's 3-Month Share Buyback Ratio for the quarter that ended in Jan. 2025 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Oct. 2024 ) - Shares Outstanding (EOP) (Jan. 2025 )) / Shares Outstanding (EOP) (Oct. 2024 )
=(148.223 - 148.223) / 148.223
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group  (OTCPK:DVHGF) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Devonian Health Group 3-Month Share Buyback Ratio Related Terms

Devonian Health Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (OTCPK:DVHGF) » Definitions » 3-Month Share Buyback Ratio
Comparable Companies
NEOE:BMND TSXV:TTI TSX:HBP TSXV:NRX XCNQ:DOSE TSX:SVA TSXV:SHRX TSX:BCT XCNQ:PHRM XCNQ:TELI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
GSD:Canada
Address
360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Website
https://www.groupedevonian.com
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.